BioNTech COO Poetting reports initial share holdings
BioNTech SE Chief Operating Officer Sierk Poetting filed an initial ownership report showing a mix of direct, indirect and derivative interests in BioNTech ordinary shares.
Rhea-AI Filing Summary
BioNTech SE Chief Operating Officer Sierk Poetting filed an initial ownership report showing a mix of direct, indirect and derivative interests in BioNTech ordinary shares. He holds options and phantom options over 18,416, 25,459, 8,838, 7,112 and 14,664 underlying ordinary shares with exercise prices including 113.9400, 185.2300 and 152.1000, expiring between 2031 and 2035. He also reports 11,047 performance share units tied to ordinary shares. In addition, he has 141,514 ordinary shares directly, 449,387 ordinary shares held through Tofino GmbH, where he is sole shareholder, and 1,638 ordinary shares held by immediate family, for which he disclaims beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Phantom Option | -- | -- | -- |
| holding | Phantom Option | -- | -- | -- |
| holding | Performance Share Unit | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (9)
- F1. The ordinary shares are held by Tofino GmbH. The Reporting Person is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by Tofino GmbH.
- F2. The ordinary shares are held by the Reporting Person's immediate family. The Reporting Person disclaims beneficial ownership of the ordinary shares noted herein except to the extent of his pecuniary interest therein.
- F3. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- F4. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.
- F5. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.
- F6. The exercise price of this option is EUR 75.91.
- F7. The exercise price of this option is EUR 93.35.
- F8. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price.
- F9. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does BioNTech (BNTX) COO Sierk Poetting report in this Form 3?
What option and phantom option positions does the BioNTech (BNTX) COO disclose?
What do the footnotes reveal about BioNTech (BNTX) COO Sierk Poetting’s indirect holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.
